Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's confusing. In our 1st quarter 10-Q, Humanigen informed us that, "We have executed a non-binding letter of intent and are engaged in exclusive negotiations relating to a proposed business combination with a privately held biopharmaceutical company (the “Partner Company”). The proposed terms for the business combination contemplate a tax-free stock-for-stock merger, as a result of which we would issue shares of our capital stock to stockholders of the Partner Company which are expected to represent roughly two times the number of our currently outstanding shares of common stock.
pg 14
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923007002/hgen-20230331.htm
When Baudax announced the acquisition of Tera-Immune, that, too, "... was structured as a stock-for-stock transaction..."
https://www.baudaxbio.com/news-and-investors/press-releases/detail/267/baudax-bio-acquires-teraimmune-inc
And somewhere along the line, for some reason, I thought we may be looking at a non-US based business combination with a subsidiary of a large Pharma. That was an overwhelming consideration. Look at J&J's subsidiaries, as I did, when I was wondering if we might enter into an agreement with Janssen, one of their subsidiaries. They've got a zillion subsidiaries.
https://www.sec.gov/Archives/edgar/data/200406/000119312512075565/d281803dex21.htm
I would prefer not to think of any type of business affiliation, to be honest. They tend to end up in litigation. I just happen to think that Novavax has more to offer than Baudax, but the question is, how valuable is Tera-Immune?
At the same time, announcing some type of merger or business combination may add fuel to the fire when we announce our loaned shares recall, and that may be the best thing about any structural change to our business. Otherwise, I just want to see management retain control of Humanigen, however we end up structured.
I used to have search capabilities on this platform, yet, even with that, it was often difficult to find information I had previously referenced, where the source of the information was linked. So I can only post what I recall. An example of that concerned the capability for potential use of the Chinese balloon to disperse biological agents. That wasn't new technology. In some US museum, there is a WWII Japanese balloon recovered on our soil that had biological disbursement capability. Another example concerned the number of shares in our float, a reported 229M. I linked the source data in real time, but we no longer have access to that data source.
As long as I have posted, about a broad array of subjects concerning Humanigen, I have tried to have a basis for my comments. But now, it seems you think I'm telling lies about a recall of our loaned shares, and a potential business partnership or merger with Baudax. Again, I've already provided the reasons for my thoughts. You're entitled to express your opinion, if you think my opinion amounts to BS. But a lie is a whole different thing.
It may be a partnership agreement for all I know. But I do think we will see a stock-for-stock transaction.
I am out of my league on this issue, and appreciate the commentary from you and others in this regard.
I truly will not be surprised if we announce the recall of our loaned shares tomorrow. I mentioned previously that I still have one open sell order, which I would LOVE to have filled.
In terms of those of us who want to enter buy orders, or to re-enter our sell orders in the US, we'll have to see if we have a chance to trade on holiday-shortened Friday.
When trading resumes, I expect sellers will be very happy. New buyers? Not so much.
But, that didn't prove to be the case after the first recall of our loaned shares. This time, however, I hope we have positive news that will prevent the full retracement of our share price to the degree seen previously.
An $8B Market Cap, at pre-forward split prices, would equate to ~$67 per share. Divide that price by 5, if management declares a 5:1 forward stock split.
I'm way out on the limb here, partner. But I'm just trying to tell you what I think we could see. I've tried to put myself in management's shoes for so long, I may not be able to look at things any other way, than the way I do.
I haven't even considered that Humanigen would agree to take on Baudax's debt and overhead.
I think management's goal is to help developers provide for a comprehensive cancer treatment line of products derived from state-of-the-art technologies, to include Treg, CAR-T, and Xspray's Hynap technology for CML, to complement our effort with AML. This is already a $2B market for Xspray, and an NDA next year could have added revenue potential, especially if lenz can be effective in enabling nilotinib to cease incurring food interactions, and eliminate the black box warning on their packaging. Lenz could be the "go-to" product for developers bringing these new platforms and therapeutics to market.
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharmas-xs003-achieves-superior-bioavailability-milestone-matching-tasigna-at-reduced-dosage/
This is frontier cancer cure territory, and lenz will be interwoven into the process.
Yeah, it's pretty scary to think about what COULD happen. But when our own universities can produce a coronavirus with an 80% kill rate, and when almost 7,000 Chinese men of military age come over the southern border in just one month, AND when the American public becomes complacent about shots that are vaccines in name only, we are poised for disaster.
At the least, we need to be prepared for the worst. We need a true vaccine, which actually helps to prevent the initial infection of covid. I think Humanigen and Novavax have that. And we need a therapeutic that will treat any variant of the virus. Lenz will not only do that, it will program an appropriate immune response to further infections, and hopefully, to reinfections, as well.
I think it is time to harvest the fruits of our effort, not only with Baudax, but with Novavax, as well. And there is opportunity beyond that, as well, with CMML. We have seen movement in all three of the illustrated opportunities.
Actually, Tank, the statement I referenced is really saying that Baudax has requested Confidential Treatment of Information they submitted in their filing. I suspect that information will be in regards to a merger with Humanigen, which WILL move the needle in terms of both allowing the company to leave the Expert Market, and avoid creditors from initiating forced bankruptcies, for both companies.
More importantly, positive news such as this merger will allow the company to announce the recall of their loaned shares THURSDAY, which is not only Thanksgiving, it is also the 8th anniversary of our first recall of loaned shares. Our partial day of trading Friday could have a significant impact on our account balances.
The filing concludes with, "Schedules have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Baudax Bio agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Baudax Bio may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished."
Baudax filed their 10-Q today for the 3rd quarter.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000095017023065200/bxrx-20230930.htm
For those who think we've already seen the worst that covid has to offer, we know that this virus has been programmed to produce an 80% kill rate, and we know that we have already discovered one illicit biolab run by Chinese nationals on US soil, with record-setting numbers of military-aged Chinese men entering the country illegally through our southern border.
The only effective weapons we will have are the Humanigen/Novavax vaccine, to prevent infections, and lenz, to treat infections. Hopefully, that will be all we need.
Did anyone notice the brief disappearance of the Form 4 yet again in the last hour? It was gone just long enough to dot an i, or cross a t. I think these shares are on their way to Baudax, and that we should be seeing an announcement in this regard at any time.
I've been watching our latest Form 4 disappear, and then reappear, including today. But I don't see any changes made to the filing. If that is correct, then maybe it is evidence of our attempt to work with the Baudax auditors, to rectify the accounting problem they identified with the acquisition of Tera-Immune. That suggests to me that the issue the auditor has may have to do with which merger sub supplied the shares Black Horse purchased, or it may be an issue of timing.
https://www.sec.gov/Archives/edgar/data/1178179/000101359423000580/baudax13ga1-07102023.htm
https://www.sec.gov/cgi-bin/browse-edgar?company=humanigen&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
But it appears that the issue is being resolved, maybe even by working on a Saturday.
But you go right ahead and continue talking about shareholders getting wiped out, all the while ignoring the potential of lenz enabling Novavax to rival Pfizer with their "game-changing" covid vaccine. And let's not even start to think about Xspray Pharma, or Gracell, and the breadth of the opportunity we are developing.
Nor take any notice of the likely recall of our loaned shares. Forget about the stellar results seen in using lenz to treat CMML, and the follow-up trial result of using lenz to prevent aGvHD, resulting in a potential cure of CMML cancer patients.
To you, any talk of our success is BS, as witnessed by your emojis. Maybe, after our success is realized, they'll have a green dollar sign emoji, and you can continue to express yourself.
I agree with eb's reply to your post. As I noted previously, I think we were only trading at $0.017 before filing the NT 10-Q, so not much of a pps reduction.
I think management has loaned 110M shares that they will recall. Likely, management will make a large number of those shares available to purchase on the Expert Market. My ideal would be that they start selling shares at $201. Shorts won't immediately be able to buy shares from the penny stock traders amongst us, who would be thrilled to sell shares at less than 5 cents.
What options do you think short sellers have at this point? Brokerages will be required to buy-in their short sellers, and issue margin calls. Management can use some of the funds from this windfall to support the bid when they move us back to OTC Pink or Venture.
I don't want to impugn Baudax's former Controller, since her merger subs were too sophisticated for me to appreciate. But for whatever the reason, she is no longer with Baudax, nor is their former Auditing Firm.
We saw Dale file his purchase of the Baudax shares, as required. Humanigen did not disclose a merger, but I don't see how we could have, since there is a problem with the accounting for the Tera-Immune acquisition.
The recall of our loaned shares is a stand alone function. I don't see how this issue could undue management's right to recall their loaned shares, if I'm right about that happening.
The impact of the recall could be historic, especially if announced with news of regulatory approval or purchase agreements. There are a number of market participants who will lose market share, or be subjected to heavy losses, if required to buy-in shares. They will use every trick in the book to prevent that, to include attacking the auditing firms. We need to be structured as defensively as possible.
But I think it's important to understand the concerns recently voiced by shareholders such as you, sosjtb, and Preciouslife1. This has been a grueling process for all of us, including management, I'm sure.
I think this was the deadline for them to regain compliance, and they didn't succeed.
No surprise, in that regard.
But we need to see a 10-Q/A from them for the 2nd quarter, in my opinion, accurately reflecting their (?) Tera-Immune acquisition. I think it was just a botched attempt to hide our role in the acquisition.
We've got other hooks to hang our hat on, most notably, Novavax. In addition, I'm hoping for CMML approval.
"I think Durrant has already prepared (the 2nd quarter 10-Q), with the possible exception of accounting for the Baudax transaction."
I think my suspicion may have been corroborated today by Baudax, who filed an NT 10-Q for the 3rd quarter, and noted the following reason for the delay.
"Baudax Bio, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (the “10-Q”) by the prescribed due date due to ongoing analysis of the accounting treatment of current and past financing transactions by the company."
https://www.sec.gov/Archives/edgar/data/1780097/000119312523278003/d882911dnt10q.htm
Why should Pfizer's paxlovid results be any less overstated than their vaccine results?
"20% of those who take Paxlovid experience rebound COVID-19, study says
Dennis Thompson, HealthDay Reporter
Tue, November 14, 2023...
About 1 in 5 people taking Paxlovid recovered and tested negative for COVID-19, but later experienced a positive test result and started shedding live and potentially contagious virus.
That's called "virologic rebound." It only happened about 2% of the time in people not taking Paxlovid, according to results published Monday in the Annals of Internal Medicine.
"We found that the virologic rebound phenomenon was much more common than expected - in over 20% of people taking Paxlovid ...
The study runs counter to clinical trials that found only 1% to 2% of patients taking Paxlovid experienced virologic rebound, the researchers noted."
https://www.yahoo.com/news/20-those-paxlovid-experience-rebound-150510652.html
When it is time to announce the recall of our loaned shares, or whenever a catalyst comes to realization, I hope that the bid gets run-up in the premarket, to help us avoid selling too cheaply.
But, if we are faced with a share price that escalates gradually, make no mistake, I will sell some shares once they yield an amount sufficient for me to pay for some badly needed home repairs that have been postponed, since I have not been supplementing my income with trading profits. Last year was the first year, in a long time, in which I did not even get a Form 1099, because I did not sell any shares.
So I fully realize the consequence of our share price.
I've worked hard, trying to understand WHAT is going on here, and worked harder, still, trying to understand WHY this is going on. I'm not looking for a supernatural resurrection, Friend. I'm counting on management having monetized the greed and corruption we have endured, to our advantage. I'm looking forward to their fulfillment of abundant value for shareholders, with full faith in the efficacy and potential of lenz, and the commitment of our management.
Reese's Peanut Butter Cups
The following article is one about a nurse who felt victimized by our health care system, and sadly ended up taking her own 28 year old life.
https://www.yahoo.com/news/emergency-room-nurse-lost-suicide-090037727.html
Never was I more aware of the demand shouldered by nurses than when I would try to "visit" my wife when she was in a Long Term Acute Care (L-TAC) center, or skilled nursing home, during the lockdown of the medical facilities, as covid raged in 2020. Nurses would have to bring my wife to a visiting window, which was no easy task, as I stood outside, hoping my wife could see me . I would try to show my appreciation to the medical staff by leaving Reese's Peanut Cups for all of them. All the facilities had policies prohibiting such gifts, but none of them turned down the Reese's Peanut Butter cups.
Anyway, I guess that's why I am re-sharing this video of the Northwell Health Nurses Choir, getting a "Golden Buzzer" for their AGT performance. I'm just glad that nurses, who went through the covid pandemic, could still find joy.
You're right, it makes no sense to file the 3rd quarter 10-Q, until the 2nd quarter 10-Q is filed, which I think Durrant has already prepared, with the possible exception of accounting for the Baudax transaction. I assume both Q's will be filed. And I further agree with you that management seems to be less concerned with financial constraints (or perhaps they wouldn't have purchased the Baudax shares on the last day of Q2). And the toughest thing about the current price per share is that we can't buy more shares at these prices.
In terms of thinking that something is up here, I think that "something" is the pending recall of our loaned shares, possibly announcing that the company owns over 90% of their issued shares.
In terms of bang for the buck, the recall will have a much bigger impact on share price than news of regulatory approvals, business combinations, mergers, PRV's, the forward stock split, or product purchase orders, including stockpile orders. But as borrowed shares become purchased, the share recall will have accomplished it's purpose, and the other catalysts will determine our sustained operational value. I previously mentioned a projected Market Cap of $8B for us. I wouldn't be surprised if it is lower...nor would I be surprised if it was higher.
Your post was excellent!
How late can a company report quarterly earnings?
"The SEC requires companies to file 10-Qs no later than 45 days after the end of a quarter, and 10-Ks must be being submitted no later than 90 days following a company's fiscal year-end."
https://www.google.com/search?q=how+long+does+a+company+have+to+report+quarterly+earnings%3F&oq=ho&gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDkyEwgCEC4YgwEYxwEYsQMY0QMYgAQyDQgDEAAYgwEYsQMYgAQyEwgEEC4YgwEYxwEYsQMY0QMYgAQyDQgFEAAYgwEYsQMYgAQyEwgGEC4YgwEYxwEYsQMY0QMYgAQyDQgHEC4YgwEYsQMYgAQyEwgIEC4YgwEYxwEYsQMY0QMYigUyBwgJEAAYjwLSAQoxMDU1NWowajE1qAIAsAIA&sourceid=chrome&ie=UTF-8
But that applies to SEC-reporting companies. How long will it take the company to leave the Equity Market? We need our resident experts to weigh in.
Yes, I know we have talked about the unchecked boxes before, but also noted the discussion in the next section of the Q somehow seemed to address that issue, as I recall (vaguely).
The reason I am glad someone asked about the recall of the loaned shares is because it gave me the chance to re-post some of the events that transpired the first time the loaned shares were recalled. Board resignations figured into that situation, too.
And not only did management fail to fight this delisting, they voluntarily provided information stating that they did not see a course to meet listing standards in the time they still had available to do so, and bowed out of consideration early.
I interpret this as management's effort to move us to the Expert Market.
To me, this was a contingency move to be able to create shareholder value by recalling the loaned shares while on the Expert Market, in case we still fail to gain regulatory approval. Management is now positioned to force buy-ins from short sellers, and they will have to buy shares from management, at the price level management will demand. That's why I asked them to establish a minimum sell price of $201. Maybe this will give me a chance to fill sell orders at $200 and $250, once Schwab can permit selling.
But it gets far better than that. I feel certain that we WILL gain regulatory approval to use lenz for the treatment of covid, as well as a vaccine adjuvant to use lenz to prevent covid, and to also use lenz to treat CMML.
This share price explosion will be unlike anything seen before! We just need to slide back to OTC Pink or Venture, on our way back to Nasdaq.
No, on August 15th, the due date for the 2nd quarter 10-Q, the closing price was $0.017. That is not 17 cents.
You said management needed to file the delinquent report, and blamed that delay for the drop in share price. I was addressing your comments.
It looks to me like the share price in mid-August, when the earnings report was due, was just over one penny. The delayed 2nd quarter 10-Q doesn't seem to be the reason for the then-already low share price.
https://ih.advfn.com/stock-market/USOTC/humanigen-ce-HGEN/historical/more-historical-data
The Baudax auditor identified a non-conformance with recording the purchase price of the Tera-Immune acquisition, which I suspect impacts Durrant's ability to adequately reflect that transaction on our 2nd quarter 10-Q.
If you don't want to recognize any other reason for the delay, such as in regards to establishing a strategic advantage for the company, then you should at least consider that Durrant shared the Baudax auditor's opinion, and needs to ensure that he would be in compliance with how he reflects our acquisition of Baudax shares on the last day of Q2.
Thank you for bringing openthebooks.com to our attention, Chaplain.
https://www.openthebooks.com/
Two notable differences:
One concerns the distinction between what Novavax refers to as their "updated vaccine", versus their "prototype vaccine."
pg 25
https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069423000055/nvax-20230930.htm
NCT05463068
ENVIRONMENTAL SCIENCE published an article last month titled "Novavax’s Covid Vaccine: The Potential Game Changer.
A New Contender Enters the Ring
The global fight against Covid-19 could see a new ally in the form of Novavax’s vaccine, NVX-CoV2373."
https://bnn.network/world/novavaxs-covid-vaccine-the-potential-game-changer/
The author is basically saying that Novavax's prototype vaccine is poised to catch up with Pfizer. It could be THIS vaccine which uses the lenz cocktail.
The other notable difference concerns the company's recalls of their loaned shares. The first time the company recalled their loaned shares, their lead product was benznidazole, designed to treat Chagas disease, and to hopefully capture a Priority Review Voucher.
Now, of course, our lead product is lenzilumab, with a successful Phase III trial behind it, designed to treat a much broader market. I mention this in regards to how much retracement we could see from the highs we will achieve immediately upon announcing the recall of our loaned shares. I expect that we will see significant share price retracement, but, especially if lenz gets regulatory approval to treat covid or CMML, we will not likely see a return anywhere near our previous highs in the $20 - $30 range.
Well, as far as the Novavax news, we have to remember that they were reporting for the 3rd Quarter. Their EU approval was dated Oct 31st. The US EUA was approved Oct 3rd. I was just hoping to pick up some hints from the 'management discussion' or 'subsequent events' portions of the filing, which is where they mentioned a prototype covid vaccine.
Even if we release our Q2 and Q3 10-Q's next week, I will look at Q3's 'management discussion' and 'subsequent events' portions of the filing. I still think a business arrangement of some sort with Novavax will yield the best revenue-related news we could hope for. And I don't think management is as concerned as they previously were about funds.
So maybe we will hear about a Priority Review Voucher associated with approval of lenz to treat CMML. I just saw a PRV sold for $105M.
Keep in mind that the first recall of our loaned shares caused a massive increase in share price without any other news, except for announcing an accumulation of a 50% ownership stake by Shkreli, which increased to 70%. I think we could announce a 92% ownership stake, if management has 110M of the 119M shares they have issued.
I just hope that we don't file another NT10-Q for the 3rd quarter. But I agree with you that we need to see "visible action occurring." So if another NT10-Q is necessary until we get regulatory approval, or whatever is necessary, we'll just have to deal with it, which I don't want to think about anymore than management does.
I found a reference to a prototype product, and a clinical trial number. Absolutely not enough information to draw a conclusion. Both the Novavax conference call, as well as the 3rd Quarter 10-Q, made note of the reduction in their R&D expense, which I had thought was too high, so I was glad to see that.
Yes, you do have the gist of it.
I actually think management already had their Transfer Agent prove their share ownership to the Nasdaq Appeals Hearing Board. I caught a reported float of 229M shares, which is 110M more shares than the company issued. The fact that the float could change by 110M shares overnight, told me that management had control of those shares. I deduced that management loaned those shares, and it is these loaned shares that I expect management will recall.
That same report also reflected an Outstanding Share total of 595,400,675 shares. That tells me that management is planning to declare a 5:1 forward stock split.
Thank you for your question. I'm super-excited to see this play out.
Here is the play-by-play of the previous recall of our loaned shares, executed by our predecessor company, Kalobios. I recall the share price actually spiking to about $248, if I recall correctly.
https://moxreports.com/kbio-infinity-squeeze/
I'd really like to think that Novavax may disclose the role that lenz played as an adjuvant, during their update tomorrow, and that Humanigen may also disclose that information tomorrow, as well. Otherwise, we'll have to wait a few more days, and hope for news in the 3rd quarter 10-Q.
The other pending regulatory news could be from Australia, regarding CMML treatment approval, or news of Emergency Use Authorization by the FDA, or the EU, for covid.
I'm more impatient, than nervous. But I know the effect the recall of our loaned shares will cause, and it could take just one filled sell order to more than restore my retirement lifestyle to what I hoped it would be.
As I recall, Sanofi was one of our initial investors. They, along with GSK, have a protein-based covid vaccine with a larger market than Novavax in the EU. I think our lenz cocktail should be compatible with the Sanofi vaccine. For all I know, even the Pfizer and Moderna vaccines could benefit from the lenz cocktail. I dismiss that, because I think lenz would interfere with the messaging of mRNA products. But even if lenz is administered subsequently, I think the mRNA vaccines would still cause the virus to mutate, and is just the wrong way to go.
But there are yet other covid vaccines approved in Europe that may benefit by using the lenz cocktail. I've previously discussed Janssen on occasion. They, along with AstraZeneca, have adenovirus vaccine compounds. So, the monstrous opportunity for lenz with Novavax could be bigger still. Novavax needs us to survive, in my opinion. They may want exclusive rights to use lenz as an adjuvant, which they need because they are not very diversified yet. But I would expect our management would be opposed to that, unless we combined our businesses, which I think would be a good move, if Novavax sized their R&D program more efficiently. I think this is a feasible possibility, since we saw Dale free-up shares that could be used in a stock-for-stock business combination with Novavax.
The suspense is killing me. The company, however, may be safer than it has ever been. If we have some type of purchase agreement with Novavax, that should entice enough buying interest for the company to recall their loaned shares, and perhaps declare the 5:1 forward stock split I have been anticipating.
For those of you who my have been wondering about our friend and former CCO, Ed Jordan, he went to Xspray Pharma after leaving Humanigen.
https://www.marketscreener.com/quote/stock/HUMANIGEN-INC-25805137/news/Humanigen-Inc-Announces-Resignation-of-Edward-Jordan-as-Chief-Commercial-Officer-44850680/
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharma-appoints-chief-commercial-officer-to-drive-upcoming-dasynoc-us-product-commercialization/
So we are without a COO, a CFO, and a CCO, and lack 2 outside Board Members. Will management seek to fill these positions, continue to assume dual roles, or will these positions be filled upon the completion of a business combination?
And who might that business partner be? Novavax is mentioned in 10 of my 16 posts featured on the X board, just sayin'.
Recognizing that I have a long-standing, pro-biased opinion of our potential with Novavax, although neither company even hints about this prospect, I am hopeful that might start to change in two days, when Novavax is scheduled to host a conference call .
"Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023"
https://ir.novavax.com/press-releases/2023-11-02-Novavax-to-Host-Conference-Call-to-Discuss-Third-Quarter-2023-Financial-Results-and-Operational-Highlights-on-November-9,-2023
I wonder if Humanigen might also announce 'Third Quarter 2023 Financial Results and Operational Highlights' at the same time. Will we see an 8-K in this regard, which also will discuss our regulatory approval from Australia for the treatment of CMML, ahead of the scheduled December 9th presentation to the American Society of Hematology (ASH)?
But, as a current shareholder, the news that I am most anticipating is the recall of the company's loaned shares.
Last week's approval by the European Commission of the 2023-2024 Novavax adjuvanted vaccine could be the biggest news yet for Humanigen. I'm expecting news in this regard any day this week.
https://ir.novavax.com/press-releases/2023-10-31-Novavaxs-Updated-COVID-19-Vaccine-Now-Approved-in-the-EU
I think "running low on funds," at this point, is no longer a concern. Management is likely to recall the 110M shares they loaned, hopefully with an initial minimum asking price of $201. If we're still on the Expert Market when the loaned shares are recalled, short sellers will be crushed. It could cost them over $22B to cover their short positions.
As I recall, $22B used to be Novavax's market cap. It could be that again. But, if their European success is due to using lenz as a supplemental/replacement adjuvant, our market cap will skyrocket, also.
Hopefully, Humanigen would get a share of the money from the Advanced Purchase Agreement funds Novavax is receiving from several European countries. Maybe that will be the start of our revenue stream.
How much momentum we retain, as we transition to OTC Pink or Venture, before returning to Nasdaq, will be interesting to watch.
I have to think, if Novavax has tested the patented lenz cocktail as an adjuvant with their covid vaccine, that lenz will replace the Matrix-M saponin-based adjuvant Novavax is currently using.
Also, might this signal a Conditional Marketing Authorization to use lenz as a treatment for infected patients in the EU?
Will such use of lenz and the lenz cocktail also enable Novavax to gain market share in Europe, well beyond the 200M - 300M projected doses?
Will Humanigen gain by the Advanced Purchase Agreements that Novavax is getting from several European countries? It may be likely that significantly less lenz can be used as an adjuvant, materially reducing the revenue per patient getting lenz. But total revenue for Humanigen would be astronomically higher due to the greatly expanded market volume of using lenz as both a prophylaxis and as a treatment.
Our newest investors may have a lower cost basis than us senior investors. But compared to what initial buyers will have to pay going forward, I think current shareholders will all be happy that we have shares ahead of the upcoming news. I just hope the bid gets run up significantly in the pre-market, once trading resumes.
I'm going to treat myself to the luxury of feeling good here this morning. Are we supposed to say "GO"? GOOOO!!
" I have always favored the Novavax... traditional compound, versus the m-RNA Pfizer and Moderna vaccines. If we can't get US authorization for the early use of lenz, based on inflammation and CRP levels, especially for people like me who are in high risk of infection and disease progression, then I would like to take the Novavax vaccine, along with lenz, in much the same way we are using lenz as a prophylactic for CAR-T toxicities.
Otherwise, I feel certain that I will eventually be diagnosed with some form of arthritis, and the leg pains I am having will show signs of clotting, and I will find myself in the same failed treatment course my wife was in, which resulted in 5 amputations on her legs, to no avail."
I am convinced that using lenz with the Novavax vaccine, as I thought was the ultimate treatment course 1 1/2 years ago, is about to become a reality in the EU. I think the US and the UK will have no choice, but to follow suit.
Quite simply, millions of preventable deaths are about to be avoided. Worldwide societies and economies will be safeguarded, including medical infrastructure.